Q1 Earnings Forecast for XENE Issued By HC Wainwright

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Xenon Pharmaceuticals in a research report issued to clients and investors on Friday, February 28th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings per share of ($1.32) for the quarter. HC Wainwright has a “Buy” rating and a $53.00 price objective on the stock. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Xenon Pharmaceuticals’ Q2 2026 earnings at ($1.27) EPS, Q3 2026 earnings at ($1.30) EPS and Q4 2026 earnings at ($1.42) EPS.

Several other analysts have also recently issued reports on the company. William Blair reiterated an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They issued a “buy” rating and a $67.00 price target on the stock. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $57.38.

Xenon Pharmaceuticals Stock Down 3.3 %

NASDAQ:XENE opened at $35.79 on Monday. The business’s 50-day simple moving average is $39.22 and its two-hundred day simple moving average is $40.31. Xenon Pharmaceuticals has a 52 week low of $33.27 and a 52 week high of $47.80. The stock has a market cap of $2.73 billion, a PE ratio of -12.69 and a beta of 1.20.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.05.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Loomis Sayles & Co. L P raised its holdings in shares of Xenon Pharmaceuticals by 7.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 707,222 shares of the biopharmaceutical company’s stock valued at $27,843,000 after purchasing an additional 46,964 shares in the last quarter. Vestal Point Capital LP increased its stake in shares of Xenon Pharmaceuticals by 57.1% in the third quarter. Vestal Point Capital LP now owns 825,000 shares of the biopharmaceutical company’s stock worth $32,480,000 after acquiring an additional 300,000 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Xenon Pharmaceuticals by 4.3% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 439,074 shares of the biopharmaceutical company’s stock worth $17,287,000 after buying an additional 17,953 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in shares of Xenon Pharmaceuticals by 1,263.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 976,783 shares of the biopharmaceutical company’s stock valued at $38,456,000 after purchasing an additional 905,129 shares during the period. Finally, Barclays PLC increased its stake in shares of Xenon Pharmaceuticals by 1,275.5% in the 3rd quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $590,000 after purchasing an additional 13,903 shares in the last quarter. Institutional investors own 95.45% of the company’s stock.

Insider Activity at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 16,315 shares of the business’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $40.50, for a total transaction of $660,757.50. Following the transaction, the chief executive officer now owns 31,302 shares of the company’s stock, valued at approximately $1,267,731. The trade was a 34.26 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Sherry Aulin sold 18,709 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. Insiders have sold a total of 57,492 shares of company stock valued at $2,334,969 over the last 90 days. 5.52% of the stock is owned by corporate insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.